ENTITY
BeiGene

BeiGene (6160 HK)

327
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
30 Nov 2023 08:55

Pre-IPO Qyuns Therapeutics - Conservative About the Outlook

Qyuns’s pipeline lacks competitiveness, facing fierce competition.Together with bleak internationalization outlook, peak sales have obvious...

Logo
289 Views
Share
26 Nov 2023 10:05

HK Short Interest Weekly: AIA, Baba, Beigene

We analyzed the latest HK SFC report for aggregate short position as of Nov 17th and highlight short interest changes in AIA, Baba, Beigene.

Logo
373 Views
Share
bearishXiaomi Corp
26 Nov 2023 05:38

Index Rebalance & ETF Flow Recap: HSI, HSCEI, HSTECH, HSCI, Div+, Top50, ASX, FXI, Xiaomi, Tata Tech

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
487 Views
Share
23 Nov 2023 08:55

2024 High Conviction – China Healthcare: It's Time to Embrace a New Era

After a period of downturn, China healthcare has found new growth point. GLP-1s is an opportunity that can't be missed and will bring substantial...

Logo
442 Views
Share
bullishBeiGene
21 Nov 2023 07:03

FXI Rebalance Preview: One Potential Change in December

Beigene could replace Anhui Conch Cement in the FXI ETF in Dec. Passives will need to trade around 2x ADV in both stocks. Shorts have increased in...

Logo
450 Views
Share
x